The FDA has long been criticized for its "revolving door" with Big Pharma where top executives move back and forth in top positions. The case of FDA approval of BioNTech's Comirnaty gene therapy injection abandoned all traditional precedents in pushing it through: incomplete data and trials, insufficient control group and no review board.
Source